logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

The U.S. FDA Approves Vertex Pharmaceuticals TRIKAFTA for Children with Cystic Fibrosis Aged 6 to 11 with Certain Mutations

Vertex Pharmaceuticals Receives FDA Approval for TRIKAFTA ® Vertex Pharmaceuticals ( VRTX ) announced the U.S. FDA approved the expanded use of TRIKAFTA® to include children with cystic fibrosis ( CF ) ages 6 through 11 years who have at least...

Read More

June 9, 2021

0

bluebird bio Provides Updated Findings of AML in LentiGlobin for SCD Gene Therapy Program

Updated Findings from bluebird bio bluebird bio analyses demonstrate lentiviral vector BB305 unlikely to be the cause of AML in a clinical study of LentiGlobin for SCD bluebird bio initiated a process with regulators to resume clinical studies bluebird bio (...

Read More

March 10, 2021

0

Vir Biotechnology and GlaxoSmithKline: Independent Data Monitoring Committee Recommends Stopping Phase 3 COMET-ICE Trial Early

Vir Biotechnology and GlaxoSmithKline Recommended to Stop Phase 3 COMET-ICE Trial Vir Biotechnology ( VIR ) and GlaxoSmithKline ( GSK ) announced that an Independent Data Monitoring Committee ( IDMC ) recommended that the Phase 3 COMET-ICE trial - the...

Read More

March 11, 2021

0

Veracyte Inc: Exciting News About nmCRPC Published Online

Veracyte Inc Decipher® Prostate Test Veracyte Inc ( VCYT ) : New data that demonstrated the prognostic utility of its Decipher® Prostate genomic classifier in men with non-metastatic castration-resistant prostate cancer ( nmCRPC ) has been published online in JAMA...

Read More

June 14, 2021

0

Jounce Therapeutics Inc Achieves First Milestone in Exclusive License Agreement with Gilead Sciences for JTX-1811

Jounce Therapeutics Inc: US FDA Cleared IND Application for JTX-1811 Targeting CCR8 Jounce Therapeutics Inc ( JNCE ) - a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that the U.S. Food...

Read More

June 15, 2021

0

Anixa Biosciences: Why This Firm Outperformed Today

Anixa Biosciences Outperformance Anixa Biosciences Inc ( ANIX ) is the worldwide licensee of a patent technology titled "Ovarian Cancer Vaccine" which was created at Cleveland Clinic. Anixa Therapeutics specializes in the treatment and prevention of cancer and infectious diseases....

Read More

March 12, 2021

0

Gilead Sciences and Merck: Long-Term Oral HIV Combination Treatment

Gilead Sciences and Merck Announced Agreement for Long-Term HIV Combination Treatment Gilead Sciences ( GILD ) and Merck ( MRK ) announced that they have entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead’s...

Read More

March 15, 2021

0

How the Stock Prices of Firms Developing Treatments or Vaccines Have Started the Day

NanoViricides and COVID-19 NanoViricides ( NNVC ), a development-stage nano-biopharmaceutical company with a proprietary and patented drug development focused on viral diseases, is among the few firms that are actively working on developing products that can treat the coronavirus disease...

Read More

March 6, 2020

0

The Small Stock That Refused to Kneel in Today's Market

Compugen Soaring in an Extremely Down Market The stocks' prices tumbled today except for very few and one of them is Compugen ( CGEN ) . This firm announced good news; we wish it has chosen a better day for...

Read More

March 9, 2020

0

AstraZeneca to Supply Half a Million Additional Doses of the Potential COVID-19 Antibody Treatment AZD7442 to the U.S.  

AstraZeneca to Supply Additional Doses of AZD7442 to the U.S. for COVID-19  AstraZeneca ( AZN ) has modified an existing agreement with the U.S. Government to supply up to 500,000 additional doses of AZD7442 - a long-acting antibody ( LAAB...

Read More

March 17, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 113
  • 114
  • 115
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy